Details for New Drug Application (NDA): 021303
✉ Email this page to a colleague
The generic ingredient in ADDERALL XR 5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.
Summary for 021303
Tradename: | ADDERALL XR 5 |
Applicant: | Takeda Pharms Usa |
Ingredient: | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate |
Patents: | 0 |
Pharmacology for NDA: 021303
Physiological Effect | Central Nervous System Stimulation |
Suppliers and Packaging for NDA: 021303
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ADDERALL XR 10 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021303 | NDA AUTHORIZED GENERIC | Sandoz Inc | 0781-2329 | 0781-2329-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2329-01) |
ADDERALL XR 10 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021303 | NDA AUTHORIZED GENERIC | Sandoz Inc | 0781-2335 | 0781-2335-01 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0781-2335-01) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 2.5MG;2.5MG;2.5MG;2.5MG | ||||
Approval Date: | Oct 11, 2001 | TE: | AB1 | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 5MG;5MG;5MG;5MG | ||||
Approval Date: | Oct 11, 2001 | TE: | AB1 | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 7.5MG;7.5MG;7.5MG;7.5MG | ||||
Approval Date: | Oct 11, 2001 | TE: | AB1 | RLD: | Yes |
Expired US Patents for NDA 021303
Complete Access Available with Subscription